Xiao Wei, Gao Zhiyong, Duan Yixing, Yuan Wuxiong, Ke Yang
Department of Urology, Hunan Provincial People's Hospital, Changsha, Hunan 410005, P.R. China.
Oncol Rep. 2015 Aug;34(2):739-46. doi: 10.3892/or.2015.4041. Epub 2015 Jun 8.
Metastasis seriously affects the clinical outcome of renal cell carcinoma patients. Despite the approval of several targeted therapies that have led to an improvement in the progression-free survival rate for these patients, advanced and metastatic renal cell carcinoma remains difficult to treat. Recently, microRNAs have been found to play a critical role in the metastatic dissemination of renal cell carcinoma cells. In the present study, we found that miR-19a expression was significantly upregulated in metastatic clear cell renal carcinoma than that in adjacent and primary carcinoma tissues using qPCR and in situ hybridization experiments. In addition, the results were confirmed in renal carcinoma cell lines. miR-19a expression in the cell lines derived from a metastatic site was higher than that in cell lines derived from a primary site. By gain- and loss-of-function experiments, we found that miR-19a acted as an oncogenic miRNA regulating renal cancer cell proliferation, migration and invasion by directly targeting PIK3CA. Furthermore, we also explored the downstream molecules of miR-19a/PIK3CA signaling. We found that Notch signaling was induced by upregulation of miR-19a, and inactivation of Notch signaling attenuated the cell proliferation, migration and invasion promoted by miR-19a. Thus, we provide evidence demonstrating that downregulation of miR-19a may be therapeutically beneficial for metastatic renal carcinoma.
转移严重影响肾细胞癌患者的临床预后。尽管多种靶向治疗药物已获批,使这些患者的无进展生存率有所提高,但晚期和转移性肾细胞癌仍然难以治疗。最近,人们发现微小RNA在肾癌细胞的转移扩散中起关键作用。在本研究中,我们通过定量聚合酶链反应(qPCR)和原位杂交实验发现,转移性透明细胞肾癌细胞中miR-19a的表达明显高于相邻和原发癌组织。此外,在肾癌细胞系中也证实了这一结果。来自转移部位的细胞系中miR-19a的表达高于来自原发部位的细胞系。通过功能获得和功能缺失实验,我们发现miR-19a作为一种致癌性微小RNA,通过直接靶向磷脂酰肌醇-3激酶催化亚基α(PIK3CA)来调节肾癌细胞的增殖、迁移和侵袭。此外,我们还探索了miR-19a/PIK3CA信号通路的下游分子。我们发现miR-19a的上调可诱导Notch信号通路,而Notch信号通路的失活可减弱miR-19a促进的细胞增殖、迁移和侵袭。因此,我们提供的证据表明,下调miR-19a可能对转移性肾癌具有治疗益处。